Rheumatoid Arthritis – United Kingdom Drug Forecast and Market Analysis

Pages: 150 Published: November 01, 2012 Report Code: GDHC1002CFR

  • Overview
  • Contents
  • Tables
  • Figures
  • Listen

GlobalData has released its new Country report, “Rheumatoid Arthritis – United Kingdom Drug Forecast and Market Analysis – Event-Driven Update”. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly’s anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ’s SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

UK physicians surveyed for this report typically follow guidelines such as NICE or BSR (British Society for Rheumatology), but also follow their own clinical experience as no two patients are the same. In the UK, about 65% of patient referrals at any stage come from PCPs. As in the US, most people seeking treatment are 55 years and older; however within this age group, males outnumber females by a small margin compared with the younger age groups.


Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in the United Kingdom including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in United Kingdom from 2011 to 2022.

Analysis of the impact of key events as well the drivers and restraints affecting the United Kingdom rheumatoid arthritis market.

Reasons to Buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of rheumatoid arthritis drug performance in the United Kingdom

Obtain sales forecast from 2011-2022 in the United Kingdom

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures



2.2Related Reports

2.3Upcoming Related Reports

3Disease Overview

3.1Etiology and Pathophysiology




3.1.4Quality of Life


4Disease Management

4.1Treatment Overview



4.2.2Clinical Practice

5Competitive Assessment


5.2Strategic Competitor Assessment

5.3Product Profiles – Major Brands

5.3.1Enbrel (etanercept)

5.3.2Humira (adalimumab)

5.3.3Remicade (infliximab)

5.3.4Simponi (golimumab)

5.3.5Cimzia (certolizumab pegol)

5.3.6Orencia (abatacept)

5.3.7Actemra/RoActemra (tocilizumab)

5.3.8Rituxan/MabThera (rituximab)

5.3.9Methotrexate Sodium (numerous generic names)


6Opportunity and Unmet Need


6.2Unmet Needs

6.2.1More rheumatologists in the field and physician knowledge of the disease

6.2.2More cost-effective therapies through oral formulation and biosimilars

6.2.3The development of predictive tests and discovery of biomarkers

6.2.4The discovery of curative therapies

6.2.5Improved drug safety and efficacy profiles

6.3Gap Analysis


6.4.1Predictive tools for diagnosis and treatment

6.4.2Target specificity

7Pipeline Assessment


7.2Promising Drugs in Clinical Development

7.2.1Tofacitinib (CP-690550)

7.2.2Tabalumab (LY2127399)

7.2.3Fostamatinib (previously R788)


7.2.5Secukinumab (AIN457)

7.2.6Masitinib (AB101)

7.2.7Baricitinib (formerly LY3009104/INCB28050)

7.2.8Sarilumab (REGN88/SAR153191)

7.2.9Sirukumab (CNTO 136)

8Market Outlook

8.1United Kingdom


8.1.2Key Events

8.1.3Drivers and Barriers





9.4Forecasting Methodology

9.4.1Diagnosed Rheumatoid Arthritis Patients

9.4.2Percent Drug-treated Patients

9.4.3Drugs Included in Each Therapeutic Class

9.4.4Launch and Patent Expiry Dates

9.4.5General Pricing Assumptions

9.4.6Individual Drug Assumptions

9.4.7Generic Erosion

9.4.8Pricing of Pipeline agents

9.5Physicians and Specialists Included in this Study

9.6Primary Research – Prescriber Survey

9.7About the Authors


9.7.2Global Head of Healthcare

9.8About GlobalData

9.9Contact Us


List of Tables

Table 1:Symptoms of Rheumatoid Arthritis

Table 2:Treatment Guidelines for Rheumatoid Arthritis

Table 3:Top Three Biologics Prescribed for Moderate-Severe Rheumatoid Arthritis by Market

Table 4:Treatment Guidelines for Rheumatoid Arthritis

Table 5:Product Profile – Enbrel

Table 6:10 year Open-label Safety and Efficacy Trial of Enbrel: Efficacy Results at 11 years for Completers

Table 7:10 year Open-label Safety and Efficacy Trial of Enbrel: Safety Results Overall

Table 8:Enbrel SWOT Analysis, 2012

Table 9:Product Profile – Humira

Table 10:Humira SWOT Analysis, 2012

Table 11:Product Profile – Remicade

Table 12:Remicade SWOT Analysis, 2012

Table 13:Product Profile – Simponi

Table 14:Simponi SWOT Analysis, 2012

Table 15:Product Profile – Cimzia

Table 16:Cimzia SWOT Analysis, 2012

Table 17:Product Profile – Orencia

Table 18:Orencia SWOT Analysis, 2012

Table 19:Product Profile – Actemra/RoActemra

Table 20:Actemra/RoActemra SWOT Analysis, 2012

Table 21:Product Profile – Rituxan

Table 22:Rituxan SWOT Analysis, 2012

Table 23:Product Profile – Methotrexate

Table 24:Methotrexate SWOT Analysis, 2012

Table 25:Summary of Minor Therapeutic Classes, 2012

Table 26:Overall Unmet Needs – Current Level of Attainment

Table 27:Clinical Unmet Needs – Gap Analysis, 2012

Table 28:Rheumatoid Arthritis – Phase Pipeline, 2012

Table 29:Comparison of Therapeutic Classes in Development for RA, 2012

Table 30:Product Profile – Tofacitinib

Table 31:Clinical Trial Locations by Country for Tofacitinib

Table 32:ORAL Standard ACR 20 Responses for Tofacitinib vs. Placebo vs. Humira at Month 6

Table 33:ORAL Step ACR 20, 50, 70 Responses for Tofacitinib vs. Placebo at Month Six

Table 34:Efficacy Issues Regarding Tofacitinib Determined by FDA Advisory Panel, May 2012

Table 35:Safety Issues Regarding Tofacitinib Determined by FDA Advisory Panel, May 2012

Table 36:Tofacitinib Clinical Trial Mortalities as of September 29, 2011

Table 37:Tofacitinib SWOT Analysis, 2012

Table 38:Product Profile – Tabalumab

Table 39:ACR Responses and DAS28 Scores for Tabalumab vs. Placebo at Week 16

Table 40:Tabalumab SWOT Analysis, 2012

Table 41:Product Profile – Fostamatinib

Table 42:ACR Responses and DAS28 Scores for Fostamatinib vs. Placebo at Month Three

Table 43:Fostamatinib SWOT Analysis, 2012

Table 44:Product Profile – RAVAX

Table 45:RAVAX SWOT Analysis, 2012

Table 46:Product Profile – Secukinumab

Table 47:Secondary Endpoint Results for Secukinumab vs. Placebo at Weeks 24 and 52

Table 48:Secukinumab SWOT Analysis, 2012

Table 49:Product Profile – Masitinib

Table 50:ACR Responses for Masitinib in the ITT Population (12 Weeks)

Table 51:ACR Responses for Masitinib in the ITT Population (12-82 Weeks)

Table 52:Masitinib SWOT Analysis, 2012

Table 53:Product Profile – Baricitinib

Table 54:ACR Responses for Baricitinib + MTX vs. Placebo + MTX at Week 12

Table 55:Safety of 4 and 8mg Baricitinib at Week 12

Table 56:Laboratory Values of 4 and 8mg Baricitinib at Week 12

Table 57:Baricitinib SWOT Analysis, 2012

Table 58:Product Profile – Sarilumab

Table 59:MOBILITY Study Results for Sarilumab at Week 12

Table 60:Sarilumab SWOT Analysis, 2012

Table 61:Product Profile – Sirukumab

Table 62:Sirukumab SWOT Analysis, 2012

Table 63:Sales Forecasts ($m) for Rheumatoid Arthritis in the United Kingdom

Table 64:Key Events Impacting Sales for Rheumatoid Arthritis in the United Kingdom, 2012

Table 65:Rheumatoid Arthritis Market – Drivers and Barriers in the United Kingdom, 2012

Table 66:Key Launch Dates

Table 67:Key Patent Expiries

Table 68:Physicians Surveyed, By Country

List of Figures

Figure 1:Healthy and Arthritic Joint with Rheumatoid Arthritis

Figure 2:Rheumatoid Arthritis Biologic Drug Targets

Figure 3:Diagnosis Criteria for Rheumatoid Arthritis Based on 2010 ACR/EULAR Criteria Point System

Figure 4:Severity of Rheumatoid Arthritis

Figure 5:Biologic Treatment Flow Based on Updated 2012 ACR Treatment Recommendations*

Figure 6:Competitive Assessment of Late-Stage Pipeline Agents in RA, 2012-2022

Figure 7:Sales for Rheumatoid Arthritis in the United Kingdom by Drug Class


Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.